Blackstone’s Triple Play: AI Data Centers, Auto Bid, and Biotech Deal
Blackstone makes bold moves across three sectors this week, signaling aggressive expansion beyond traditional asset management. The firm launches a publicly traded vehicle targeting AI data center acquisitions, aiming to tap retail investor capital after securing anchor investments from sovereign wealth funds.
Simultaneously, Blackstone and Brookfield have entered the €8 billion bidding war for Volkswagen's Everllence SE diesel unit—a contrarian bet on legacy auto assets. The firm's Life Sciences arm meanwhile struck a co-funding deal with Johnson & Johnson to advance AML cancer drug bleximenib.
RBC Capital endorsed the strategy with an Outperform rating and $179 price target. The AI data center play proves most controversial, with some investors questioning whether remote facilities may become obsolete amid rapid technological evolution.
